Technology evaluation: Onyvax-P, Onyvax

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 5, 2005, Pages 511-519

  Doehn, Christian ^a   Böhmer, Torsten ^a   Jocham, Dieter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; ONYVAX P;

ARTHRALGIA; BACKACHE; CANCER CELL CULTURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; MALE; NAUSEA; NONHUMAN; PROSTATE CANCER; PRURITUS; REVIEW; SKIN BRUISING; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; VACCINATION; VOMITING;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 27144517135     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 263929 Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Mosmann TR, Coffman RL ANNU REV IMMUNOL 1989 7 145-173
2. 318749 St George's hospital establishes vaccine trial for prostate cancer. INTERNET SITE 1999 March 18
3. 328379 A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA), in advanced prostate cancer. Eder JP, Kantoff PW, Roper K, GuangXian X, Oh WK, Bubley G, Kaufman D, Panacali D, Tsang A, Schlom J, Kufe DW PROC AM SOC CLIN ONCOL 1999 18 Abs 1692
4. 362724 Immune reactivity of prostate cancer patients vaccinated with allogeneic cell vaccines during a phase I clinical trial. Guckian MP, Labarthe MC, Haley JL, Compton L, Guile K, Nicholson S, Perry M, Eaton J, Kirby R PROC AM ASSOC CANCER RES 2000 41 Abs 4019
5. 367772 AVAX Technologies' O-Vax cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer. Data presented at the Annual Meeting of the American Society of Clinical Oncology. PRESS RELEASE AVAX Technologies Inc 2000 May 22
6. 381596 Promising therapeutic vaccine for prostate cancer enters expanded clinical studies - National Cancer Institute sponsors additional phase II trials for Therion Biologics' PROSTVAC VF. PRESS RELEASE Therion Biologics Corp 2000 September 07
7. 441036 Beeson Gregory and Weil Gotshal & Mangos Cancer Therapies Conference and Exhibition 2002, London, UK, 20 February 2002. Zarkowska T IDDB MEETING REPORT 2002 February 20
8. 467347 Technology evaluation: PROSTVAC, Therion. Doehn C, Jocham D CURR OPIN MOL THER 2002 4 5 528-534
9. 488905 Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler HJ, Tomaszewski JE, Hodge JW, Schlom J, Kantor JA, Tyson CA, Donohue SJ INT J CANCER 2000 85 4 508-517
10. 493528 Preliminary results of a phase VII study to determine the safety, tolerability and efficacy of the allogeneic whole cell vaccine in patients with hormone refractory prostate cancer. Michael A, Quatan N, Whelan M, Kendall A, Pandha H PROC AM SOC CLIN ONCOL 2003 22 Abs 752
11. 506650 Berns Biotech to produce Onyvax-P for Onyvax. Berna Biotech Ltd PRESS RELEASE 2003 September 23
12. 545388 The effect of whole cell allogeneic vaccination on the progression of hormone-relapsed prostate cancer. Pandha HS, Michael A, Quatan N, Wushishi F, Russell N, Whelan J, Whelan M PROC AM SOC CLIN ONCOL 2004 23 Abs 4735
13. 563360 Allogenic whole cell vaccination significantly delays disease progression in hormone-relapsed prostate cancer: Final data from a phase II study. Michael A, Quatan N, Russel N, Wushishi F, Whelan J, Whelan M, Pandha H EUR J CANCER SUPPL 2004 2 8 Abs 260
14. 567103 Cytokine responses to an irradiated allogenic whole cell vaccine for human prostate cancer: A serial evaluation by CBA and real time PCR techniques. Whelan M, Michael A, Russell N, Whelan J, Wushishi F, Barren D, Pandha H PROC AM ASSOC CANCER RES 2003 94 Abs 3874
15. 567106 Immunotherapeutic potential of whole tumor cells. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H, Todryk S CANCER IMMUNOL IMMUNOTHER 2002 51 7 351-357
16. 567107 Strategies to improve murine melanoma allogeneic vaccine using cytokine gene transfection. Ward SJ, Halanek N, Birchall LJ, Desel C, Russell N, Whelan M, Dalgleish AG BR J CANCER 2002 86 Suppl 1 109
17. 567108 Tumor-stromal-endothelial cell interactions may provide a second-generation vaccine for prostate cancer. Haley J, Lane E, Stevenson D PROC AM ASSOC CANCER RES 2001 92 Abs 841
18. 567110 Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumor cell vaccines. Todryk SM, Birchall LJ, Erlich R, Halanek N, Orleans-Lindsay JK, Dalgleish AG IMMUNOLOGY 2001 102 2 190-198
19. 579412 Monitoring of immunological changes after administration of a whole cell allogeneic prostate cancer vaccine. Whelan MA, Michael A, Quatan N, Russell N, Whelan J, Wushishi F, Pandha H BR J CANCER 2003 88 Suppl 1 16
20. 586133 Onyvax US clinical advisory board reviews phase II data and gives input to Onyvax-P late-stage clinical trial design in prostate cancer. Onyvax Ltd PRESS RELEASE 2005 February 21
21. 592010 Onyvax Ltd - Company World Wide Website. Onyvax Ltd COMPANY WORLD WIDE WEB SITE 2005 February 23
22. 594690 Onyvax vaccine therapies corporate fact sheet. Onyvax Ltd COMPANY PUBLICATION 2005 April 01
23. 594911 Drug development update: Status of clinical trials of Onyvax-CR and Onyvax-105. COMPANY COMMUNICATION 2005 April 13
24. 601659 Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC). Small EJ, Schellhammer PF, Higano CS, Neumanaitis J, Valone F, Hershberg R PROC AM SOC CLIN ONCOL 2005 24 Abs 4500
25. 608183 Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J, Chakraborty P, Leader D, Whelan M, Pandha H CLIN CANCER RES 2005 11 12 4469-4478
26. 615178 The development of therapeutic vaccines of the management of malignant melanoma. Dalgleish AG, Souberbielle BE CANCER SURV 1996 26 289-319
27. 615179 Increased time to progression and sustained PSA velocity responses in a phase II trial in advanced metastatic prostate cancer following treatment with ONY-P1, an allogeneic whole cell vaccine. Dalgleish AG, Quatan N, Michael A, Wushishi F, Pandha H J CLIN ONCOL 2005 23 16S Abs 4726
28. 615180 Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Dawson LA, Maitland NJ, Turner AJ, Usmani BA BR J CANCER 2004 90 8 1577-1582
29. 615182 Allogeneic whole-cell vaccine: A phase I/II study in men with hormone-refractory prostate cancer. Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS BJU INT 2002 89 1 19-26
30. 615183 Molecular biology of the androgen receptor: From molecular understanding to the clinic. Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H EUR UROL 2001 40 3 241-251
31. 615184 Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Gulley JL, Aden PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K et al CLIN CANCER RES 2005 11 9 3353-3362
32. 615185 The LNCaP cell line - a new model for studies on human prostatic carcinoma. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA PROG CLIN BIOL RES 1980 37 115-112
33. 615186 Allogeneic whole-tumor cell vaccination in the rat model of prostate cancer. Hrouda D, Todryk S, Perry MJ, Souberbielle BE, Kayaga J, Kirby RS, Dalgleish AG BJU INT 2000 86 6 742-748
34. 615187 Cancer statistics, 2005. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ CA CANCER J CLIN 2005 55 1 10-30
35. 615189 The natural history of prostate cancer. Kessler B, Albertsen P UROL CLIN NORTH AM 2003 30 2 219-226
36. 615190 In vitro modelling of opithelial and stromal interactions in non-malignant and malignant prostates. Lang SH, Slower M, Maitland NJ BR J CANCER 2000 82 4 990-997
37. 615191 Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. Li M, Davey GM, Sutherland RM, Kurts C, Lew AM, Hirst C, Carbone FR, Heath WR J IMMUNOL 2001 166 10 6099-6103
38. 615192 In vitro models to study cellular differentiation and function in human prostate cancers. Maitland NJ, Macintosh CA, Hall J, Sharrard M, Quinn G, Lang S RADIAT RES 2001 155 1 Pt 2 133-142
39. 615193 Tumor vaccines for the management of prostate cancer. McNeel DG, Disis ML ARCH IMMUNOL THER EXP (WARSZ) 2000 48 2 85-93
40. 615197 Immune-based therapies for prostate cancer. McNeel DG, Malkovsky M IMMUNOL LETT 2005 96 1 3-9
41. 615199 Androgen deprivation therapy for prostate cancer: Current status and future prospects. Miyamoto H, Messing EM, Chang C PROSTATE 2004 61 4 332-353
42. 615203 Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy. Pandha HS, Cook D, Greenhalgh R, Dalgleish AG BJU INT 2005 95 9 1336-1343
43. 615204 Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy. Pandha H, Eaton J, Greenhalgh R, Soars D, Dalgleish A CANCER GENE THER 2005 12 6 572-578
44. 615210 Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC J CLIN ONCOL 1996 14 6 1756-1764
45. 615211 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA N ENGL J MED 2004 351 15 1502-1512
46. 615212 The human prostatic carcinoma cell line LNCaP and its derivatives. An overview. van Steenbrugge GJ, Groen M, van Dongen JW, Bolt J, van der Korput H, Trapman J, Hasenson M, Horoszewicz J UROL RES 1989 17 2 71-77
47. 615343 Vaccination immunotherapy - an update. Doehn C, Jocham D SCAND J SURG 2004 93 2 163-169
48. 615345 Recent progress in management of advanced prostate cancer. Kantoff P ONCOLOGY (HUNTINGT) 2005 19 5 631-636
49. 616321 Allogeneic murine melanoma cell vaccine: A model for the development of human allogeneic cancer vaccine. Knight BC, Souberbielle BE, Rizzardi GP, Dalgleish AG MELANOMA RES 1996 6 4 229-306
50. 618217 Heated tumor cells of autologous and allogeneic origin elicit anti-tumor immunity. Todryk SM, Eaton J, Birchall L, Greenhalgh R, Soars D, Dalgleish AG, Melcher AA, Pandha HS CANCER IMMUNOL IMMUNOTHER 2004 53 4 323-330